TY - JOUR
T1 - Acute Effects of 2C-E in Humans
T2 - An Observational Study
AU - Papaseit, Esther
AU - Olesti, Eulalia
AU - Pérez-Mañá, Clara
AU - Torrens, Marta
AU - Grifell, Marc
AU - Ventura, Mireia
AU - Pozo, Oscar J
AU - de Sousa Fernandes Perna, Elizabeth B.
AU - Ramaekers, Johannes G.
AU - de la Torre, Rafael
AU - Farré, Magí
N1 - Copyright © 2020 Papaseit, Olesti, Pérez-Mañá, Torrens, Grifell, Ventura, Pozo, de Sousa Fernandes Perna, Ramaekers, de la Torre and Farré.
PY - 2020/3/18
Y1 - 2020/3/18
N2 - 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2A), 2B (5-HT2B), and (5-HT2C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
AB - 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2A), 2B (5-HT2B), and (5-HT2C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
KW - 2C-E (2
KW - 3,4-METHYLENEDIOXYMETHAMPHETAMINE
KW - 5-Dimethoxy-4-ethylphenethylamine)
KW - BEVERAGE AYAHUASCA
KW - ECSTASY
KW - EXPERIENCES
KW - HUMAN PHARMACOLOGY
KW - PSYCHOACTIVE SUBSTANCE USE
KW - RECEPTOR
KW - REGULAR PSYCHOSTIMULANT USERS
KW - SAMPLE
KW - novel psychoactive substances (NPS)
KW - phenylethylamines
KW - psychedelic
KW - psychostimulants
U2 - 10.3389/fphar.2020.00233
DO - 10.3389/fphar.2020.00233
M3 - Article
C2 - 32256350
SN - 1663-9812
VL - 11
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 233
ER -